<DOC>
	<DOCNO>NCT02515448</DOCNO>
	<brief_summary>Ventilator associate pneumonia ( VAP ) remain intensive care unit infection associate high morbidity mortality . Respiratory infection resistant organism increase prevalence . Because lack alternative , amino glycoside , old antibiotic family , use several infection . Aerosolized Amikacin Tobramycin use mechanically ventilated patient respiratory infection . Gentamicin , effective numerous multi drug resistant Gram-negative organism Gram-positive like Staphylococcus aureus , could great option nebulisation . The investigator assume nebulisation gentamicin allow obtain high lung concentration assure systematic toxicity much less parenteral administration .</brief_summary>
	<brief_title>A Pharmacokinetic-pharmacodynamic Dose Comparison Study 8 mg/kg Inhaled Parenteral Gentamicin 12 Mechanically Ventilated Critically Ill Patients Treated Ventilator-associated Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>critical care unit mechanically ventilate ventilatorassociated pneumonia require treatment gentamicin affiliate national insurance scheme give informed consent ( patient close person ) obese ( BMI &gt; 40 kg/m² ) treat gentamicin 7 day allergic aminoglycoside severe respiratory failure ( PaO2 / FiO2 &lt; 150 ) renal failure ( Cl creat &lt; 60 ml/min/1.73m² ) reinforce protection measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>VAP</keyword>
	<keyword>Critical care</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Gentamicin</keyword>
</DOC>